Table 3.

Factors of lung cancers among AChEI subgroups by using Cox regression and Fine and Gray's competing risk model.

AChEI subgroups	Rate (per 105 PYs)	Adjusted HR	95% CI	95% CI	P
Without AChEI	362.52	Reference
With AChEI	371.04	1.198	0.765	1.774	0.167
With Donepezil	367.91	1.188	0.759	1.759	0.189
With Donepezil, 1–30 days	363.38	1.173	0.749	1.737	0.204
With Donepezil, 31–365 days	369.39	1.193	0.762	1.766	0.187
With Donepezil, 366–730 days	365.10	1.179	0.756	1.747	0.201
With Donepezil, ≥ 731 days	372.94	1.204	0.769	1.783	0.158
With Rivastigmine	369.48	1.194	0.862	1.685	0.225
With Rivastigmine, 1–30 days	362.63	1.173	0.743	1.642	0.313
With Rivastigmine, 31–365 days	364.59	1.178	0.751	1.659	0.286
With Rivastigmine, 366–730 days	373.47	1.245	1.041	1.884	0.003
With Rivastigmine, ≥ 731 days	375.29	1.297	1.043	1.889	0.001
With Galantamine	367.70	1.187	0.905	1.825	0.165
With Galantamine, 1–30 days	363.11	1.172	0.849	1.734	0.297
With Galantamine, 31–365 days	365.14	1.179	0.853	1.749	0.183
With Galantamine, 366–730 days	366.48	1.183	0.884	1.755	0.145
With Galantamine, ≥ 731 days	375.01	1.211	1.070	1.978	< 0.001

PYs person-years, Adjusted HR adjusted hazard ratio: adjusted for the variables listed in Table 3, CI confidence interval.